Drug Profile
Research programme: monoclonal antibody therapeutics - IMED
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator IMED AB
- Class Monoclonal antibodies
- Mechanism of Action Apoptosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Graft-versus-host disease; Immunological disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Graft-versus-host-disease in Sweden (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Immunological-disorders in Sweden (Parenteral)
- 29 Sep 2009 Preclinical development is ongoing in Sweden